Ablynx

Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis

Shots: Merck to receive an € 50M upfront payment and € 400M development and commercial milestones and royalties on future net sales. Novartis will hold full responsibility for the development and commercialization of the M6495 program Two P-I studies were completed with M6495 where NCT03224702 in healthy volunteers demonstrated safety and tolerability and reduction of …

Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis Read More »

Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out

Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after a 23 million euro ($27 million) financing round. ExeVir is a spin-out of Vlaams Instituut voor Biotechnologie (VIB), Belgium’s life sciences research institute and the company also has backing from UCB Ventures, and specialist European life sciences …

Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find out Read More »